ArticleBMC pulmonary medicine2026
Rare transformation from small cell lung cancer to lung squamous cell carcinoma: a case report.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDespite the evolution of treatment for extensive-stage small cell lung cancer (ES-SCLC) and advanced non-small cell lung cancer (NSCLC), drug resistance remains a major clinical challenge. Histological transformation is one of the key mechanisms. Previous studies mostly reported transformation from NSCLC to SCLC. Here we reported a patient with lung squamous cell carcinoma transformation from SCLC after multiple lines of treatment. CASE DESCRIPTION: A 60-year-old male patient was diagnosed with ES-SCLC (cT4N3M1a) in October 2022. In addition to first-line chemotherapy, immunochemotherapy with or without anti-angiogenic agent was used in the subsequent treatment lines. Given the elevation of squamous cell carcinoma markers during third-line treatment, the patient underwent the second biopsy. The pathological examination showed transformation from SCLC to lung squamous cell carcinoma, which was confirmed by the third biopsy. Finally, the patient died due to acute massive cerebral infarction on November 30, 2025, which was unrelated to treatment or cancer.
conclusionsThis rare case highlights the importance of re-biopsy during the disease course, especially for patients with poor response. We hope that this case can provide reference for physicians in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.